WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 200...(- 19.7 12.9 49% 22.0 - 23.0 13....)

Manufacturing

Services 2.7 - 3.2 3.1 (5%) 3.9 - 4.4 3.1 34%

Operating Income 6.7 - 8.2 7.5 (1%) 13.7 - 15.2 9.0 61%

EBITDA 13.9 - 15.4 10.2 44% 17.0 - 18.5 11.7 52%

* Growth rate calculated based on mid-point range

Financial data presented on a non-GAAP basis exclude share-based compensation expenses and amortization of acquired intangible assets. The non-GAAP measures are reconciled to the corresponding GAAP measures in the section below titled "Use of Non-GAAP Financial Measures".

Commenting on the third quarter 2008 preliminary results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "WuXi continues its historical trend of delivering strong revenue and profitability growth, as reflected in the 96% top-line revenue and 52% non-GAAP EBITDA growth (each using the mid-point of current estimates). As we enter the fourth quarter, we expect lower than anticipated full-year 2008 revenues, due to cancelled or delayed projects from small biotechnology customers. However, our China-based laboratory services business remains strong and is expected to grow over 40%, year-over-year.

"Even with the financial market unrest, we believe the need for outsourced services remains robust. WuXi has an outstanding reputation for providing high-quality, IP-protected services in a cost-effective and efficient manner. In all environments, we are positioned to meet and anticipate our customer needs, by expanding and evolving our services, while maintaining our focus on revenue growth and profitability."

Expected third quarter 2008 operating income reflects expected sales, general and administrative expenses (excluding share-based compensation) generally consistent with the second quarter of 2008.

On November 12, 2008, WuXi expects to announce finalized operating results (including
'/>"/>